Weight Changes in Patients Using Nurtec ODT: Patient-Reported Outcomes from a Real-World Survey

Weight Changes Associated with Rimegepant

Abstract

Background: Nurtec ODT (rimegepant) is a calcitonin gene-related peptide (CGRP) receptor antagonist approved for acute and preventive treatment of migraine in adults. Clinical trials have primarily focused on efficacy and headache-related adverse events; however, anecdotal evidence and patient feedback suggest a potential association between Nurtec ODT and weight changes.

Objectives: To assess real-world, patient-reported experiences of weight change following initiation of Nurtec ODT and to determine whether patients attributed these changes to the medication.
Methods: A cross-sectional online survey was conducted among Nurtec ODT users. Respondents reported weight changes over a three-month period and provided self- assessment regarding the extent of change and whether they attributed the change to Nurtec ODT.

Results: Of the 32 respondents, 29 (91%) reported a change in weight after starting Nurtec ODT. Weight gain of 5–10 lbs was reported by 55%, while 19% reported gaining more than 10 lbs. Weight loss was reported by 12%, and 10% noted no significant change. Among those with weight changes, 86% believed Nurtec ODT was the primary cause.

Conclusion: A considerable proportion of Nurtec ODT users reported moderate weight gain within three months of use, with most attributing the change to the medication. Although weight changes are not listed as adverse events in clinical trial data, these real-world findings underscore the need for pharmacovigilance and further clinical investigation.